HIV-1 and HCV viral load cost models for bDNA: 440 Molecular System versus real-time PCR AmpliPrep®/TaqMan® test

Expert Review of Molecular Diagnostics

Volumn 7, Issue 6, 2007, Pages 723-753

  Elbeik, Tarek ^a,b   Dalessandro, Ralph ^c   Loftus, Richard A ^b,d   Beringer, Scott ^a,b  

^a Health Management Institute Inc   (United States)

^b Newbridge Technology ^*  (United States)

^c Newbridge Technology   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

AmpliPrep Taqman Test; bDNA assay; Comparative study; Costs and cost analysis; Polymerase chain reaction; Real time PCR; Viral load

Indexed keywords

ARTICLE; BIOLOGICAL MODEL; CONTROLLED STUDY; COST CONTROL; DISPOSABLE EQUIPMENT; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; MARKETING; MEDICAL INSTRUMENTATION; MOLECULAR COMPUTER; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD;

BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; COSTS AND COST ANALYSIS; DNA, VIRAL; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 36448966825     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.6.723     Document Type: Article

References (41)

1. Hammer SM, Saag MS, Schechter M et al. Treatment for Adult HIV infection. Recommendations of the International AIDS Society - USA Panel. J. Amer. Med. Assoc. 296(7), 827-843 (2006).
2. Department of Veterans Affairs Hepatitis C Resource Center; Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am. J. Gastroenterol. 101(10), 2360-2378 (2006).
3. Terrault NA, Pawlotsky JM, McHutchison J et al. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. J. Vir. Hep. 12(5), 465-472 (2005).
4. Calmy A, Ford N, Hirschel B et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin. Infect. Dis. 44(1), 128-134 (2007). • Significant paper that insists on the need for affordable viral load testing in resource-limited countries.
5. Rouet F, Rouzioux C. The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin. Lab. 53(3-4), 135-148 (2007). • Significant work describing various viral load tests and the benefits and/or drawbacks of their application in resource-limited countries. Also reports on a more realistic viral load test price for resource-limited countries.
6. de Lamballerie X, Colson P. The battle against infectious diseases in developing countries: the inseparable twins of diagnosis and therapy. Clin. Chem. 52(7), 1217 (2006). • Significant paper that insists on the need for affordable viral load testing in resource-limited countries.
7. Stevens G, Rekhviashvili N, Scott LE, Gonin R, Stevens W. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J. Clin. Microbiol. 43(2), 857-861 (2005).
8. Steegen K, Demecheleer E, De Cabooter N et al. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J. Virol. Methods 133(2), 137-145 (2006).
9. Drosten C, Panning M, Drexler JF et al. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5′ long terminal repeat domain clinical chemistry. Clin. Chem. 52(7), 1258-1266 (2006).
10. Rouet F, Ekouevi DK, Chaix ML et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43(6), 2709-2717 (2005). • Informative example of setting up a low-cost home brew PCR viral load tests in a resource-limited country.
11. Elbeik T, Markowitz N, Nassos P et al. Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow. J. Clin. Microbiol. 42(7), 3120-3127 (2004).
12. Elbeik T, Delassandro R, Chen YMA, Soutchkov SV, Loftus, RA, Beringer S. Global cost modeling analysis of HIV-1 and HCV viral load assays. Exp. Rev. Pharmacoeconomics Outcomes Res. 3(4), 383-407 (2003). • First and only published work of a comparative viral load cost model.
13. Schrijver I, Baron E J. Labor and cost requirements of two commercial assays for qualitative molecular detection of hepatitis C virus. J. Clin. Microbiol. 40(9), 3476-3477 (2002).
14. Elbeik T, Charlebois E, Nassos P et al. Quantitative and cost comparison of ultrasensitive HIV-1 RNA viral load assays: Bayer bDNA Quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor MONITOR version 1.5. J. Clin. Microbiol. 38(3), 1113-1120 (2000). • First in-depth study to report on the cost of two different viral load tests.
15. Tsongalis GJ. Branched DNA technology and molecular diagnostics. Am. J. Clin. Pathol. 126(3), 448-453 (2006).
16. Elbeik T, Loftus RA, Beringer S. Health care industries' perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay. Expert Rev. Mol. Diagn. 2(3), 275-285 (2002).
17. Schumacher W, Frick E, Kauselmann M, Maier-Hoyle V, van der Vliet R, Babiel R. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J. Clin. Virol. 38(4), 304-312 (2007).
18. Gleaves CA, Welle J, Campbell M et al. Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance. J. Clin. Virol. 25(2), 205-216 (2002).
19. Elbeik T, Surtihadi J, Destree M et al. Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J. Clin. Microbiol. 42(2), 563-569 (2004).
20. Sizmann D, Boeck C, Boelter J et al. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J. Clin. Virol. 38(4), 326-333 (2007).
21. Wittek M, Stürmer M, Doerr HW, Berger A. Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev. Mol. Diagn. 7(3), 237-246 (2007). • Review of both viral load and genotypic resistance tests.
22. Fiscus SA, Cheng B, Crowe SM et al. Forum for collaborative HIV research alternative viral load assay working group. HIV-1 viral load assays for resource-limited settings. PLoS Med. 3(10), E417 (2006). • Review of various viral load tests and the challenges faced in setting up viral load testing centers in resource-limited countries.
23. Preiser W, Drexler JF, Drosten C. HIV-1 viral load assays for resource-limited settings: clades matter. PLoS Med. 3(12), E538 (2006). • Critical paper stressing that price alone cannot be considered when selecting a viral load test; performance characteristics must be acceptable for effective clinical care.
24. Rouet F, Chaix ML, Nerrienet E et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J. Acquir. Immune Defic. Syndr. 45(4), 380-388. (2007) • Significant paper describing superior subtype detection using a homebrew real-time PCR assay versus commercial assays (Amplicor v1.5 and bDNA).
25. Steegen K, Luchters S, De Cabooter N et al. Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J. Virol. Methods (2007) (Epub ahead of print).
26. Berger A, Scherzed L, Sturmer M, Preiser W, Doerr HW, Rabenau HF. Comparative evaluation of the Cobas Amplicor HIV-1 MONITOR ultrasensitive test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 MONITOR ultrasensitive test and the VERSANT HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. J. Clin. Virol. 33(1), 43-51 (2005).
27. Martin DJ, Sim J. Requirements for scaling up HIV treatment. Southern African HIV Clinicians Society and Toga Labs, Johannesburg. Session 3 Symposium: Scaling Up HIV in the Developing World. Presented at: The 12th Conference on Retroviruses and Opportunistic Infections. Hynes Convention Center, Boston, MA, USA 22-25 February 2005 (Abstract 3).
28. James JS. Clinton Foundation negotiates $140/Year HIV treatment, but U.S. won't buy. AIDS Treat. News 399, 2-4 (2004).
29. Brinkman K. The price of HIV treatment. Neth. J. Med. 61(12), 391-392 (2003).
30. Sharma DC. ARV prices nosedive after Clinton brokering. Lancet 362(9394), 1467 (2003).
31. Elbeik T, Nassos P, Kipnis P, Haller B, Ng VL. Evaluation of the VACUTAINER PPT Plasma Preparation Tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA. J. Clin. Microbiol. 43(8), 3769-3771 (2005).
32. Holodniy M, Rainen L, Herman S, Yen-Lieberman B. Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. J. Clin. Microbiol. 38(1), 323-326 (2000).
33. Antiretroviral therapy for HIV infection for adults and adolescents in resource limited settings: towards universal access. Recommendations for a public health approach. 2006 revision. WHO, 2006 www.who.int/hiv/pub/guidelines/ who%20adult%20art%20guidelines.pdf
34. December 06 AIDS Epidemic Update, Joint United Nation on HIVAIDS (UNAIDS) and World Health Organization, 2006 http://data.unaids.org/pub/epireport/2006/ 2006_epiupdate_en.pdf
35. Factsheet 164. Hepatitis C, Revised October 2000. www.who.int/ mediacentre/factsheets/fs164/en/index.html
36. William J. Clinton Foundation. www.clintonfoundation.org/cf-pgm-hs- aiwork3.htm
37. Sources and prices of selected medicines and diagnostics for people living with HIV/AIDS - a joint UNICEF, UNAIDS, WHO, MSF project. 6th Edition www.who.int/hiv/amds/sourcesaug05.pdf
38. Fisher Scientific Online Catalog, October 2006 www1.fishersci.com/browse? cid=1328
39. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Developed by the DHHS panel on antiretroviral guidelines for adults and adolescents. A working group of the Office of AIDS Research Advisory Council (OARAC) www.aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf
40. + tests for developing countries by as much as 80%, 2004 www.thebody.com/content/ policy/art10758.html
41. Beckman Coulter ships 80,000 HIV/AIDS monitoring tests to South Africa under Clinton Foundation deal. www.thebody.com/content/world/art10251.html